Jump to content

Dementia

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 124.81.45.228 (talk) at 09:32, 15 June 2010 (→Risk to self and others). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

For other uses, see Dementia (disambiguation).
Dementia
SpecialtyPsychiatry, neurology Edit this on Wikidata
Frequency3.8—4% (Asia), 6.1—6.3% (Europe), 6.4—6.6% (Americas), 2.5—2.7% (Africa)

Dementia (meaning "deprived of mind") is a serious loss of cognitive ability in a previously unimpaired person, beyond what might be expected from normal aging. It may be static, the result of a unique global brain injury, or progressive, resulting in long-term decline due to damage or disease in the body. Although dementia is far more common in the geriatric population, it may occur in any stage of adulthood.

The overwhelming factor emerging from genetic studies of the dementias and other central nervous system neurodegenerative conditions is abnormalities of protein handling.[1]

This age cutoff is defining, as similar sets of symptoms due to organic brain syndrome or dysfunction, are given different names in populations younger than adult. Up to the end of the nineteenth century, dementia was a much broader clinical concept.[2]

Dementia is a non-specific illness syndrome (set of signs and symptoms) in which affected areas of cognition may be memory, attention, language, and problem solving. It is normally required to be present for at least 6 months to be diagnosed;[3] cognitive dysfunction that has been seen only over shorter times, in particular less than weeks, must be termed delirium. In all types of general cognitive dysfunction, higher mental functions are affected first in the process.

Especially in the later stages of the condition, affected persons may be disoriented in time (not knowing what day of the week, day of the month, or even what year it is), in place (not knowing where they are), and in person (not knowing who they are or others around them). Dementia, though often treatable to some degree, is usually due to causes that are progressive and incurable.[citation needed]

Symptoms of dementia can be classified as either reversible or irreversible, depending upon the etiology of the disease. Less than 10% of cases of dementia are due to causes that may presently be reversed with treatment. Causes include many different specific disease processes, in the same way that symptoms of organ dysfunction such as shortness of breath, jaundice, or pain are attributable to many etiologies.

Without careful assessment of history, the short-term syndrome of delirium (often lasting days to weeks) can easily be confused with dementia, because they have all symptoms in common, save duration, and the fact that delirium is often associated with over-activity of the sympathetic nervous system.[citation needed] Some mental illnesses, including depression and psychosis, may also produce symptoms that must be differentiated from both delirium and dementia.[4]

Chronic use of substances such as alcohol can also predispose the patient to cognitive changes suggestive of dementia,[5] although moderate intake may have a protective effect.[6]

Signs and symptoms

Comorbidities

Dementia is not merely a problem of memory. Additional mental and behavioral problems often affect people who have dementia, and may influence quality of life, caregivers, and the need for institutionalization.

Depression affects 20–30% of people who have dementia, and about 20% have anxiety.[7] Psychosis (often delusions of persecution) and agitation/aggression also often accompany dementia. Each of these needs to be assessed and treated independent of the underlying dementia.[8]

Risk to self and others

The Canadian Medical Association Journal has reported that driving with dementia could lead to severe injury or even death to self and others. Doctors should advise appropriate testing on when to quit driving.Cite error: A <ref> tag is missing the closing </ref> (see the help page).[9][10] Hypothyroidism sometimes causes slowly progressive cognitive impairment as the main symptom, and this may be fully reversible with treatment. Normal pressure hydrocephalus, though relatively rare, is important to recognize since treatment may prevent progression and improve other symptoms of the condition. However, significant cognitive improvement is unusual.

Dementia is much less common under 65 years of age. Alzheimer's disease is still the most frequent cause, but inherited forms of the disease account for a higher proportion of cases in this age group. Frontotemporal lobar degeneration and Huntington's disease account for most of the remaining cases.[11] Vascular dementia also occurs, but this in turn may be due to underlying conditions (including antiphospholipid syndrome, CADASIL, MELAS, homocystinuria, moyamoya and Binswanger's disease). People who receive frequent head trauma, such as boxers or some martial artists, are at risk of dementia pugilistica.

In young adults (up to 40 years of age) who were previously of normal intelligence, it is very rare to develop dementia without other features of neurological disease, or without features of disease elsewhere in the body. Most cases of progressive cognitive disturbance in this age group are caused by psychiatric illness, alcohol or other drugs, or metabolic disturbance. However, certain genetic disorders can cause true neurodegenerative dementia at this age. These include familial Alzheimer's disease, metachromatic leukodystrophy, SCA17 (dominant inheritance); adrenoleukodystrophy (X-linked); Gaucher's disease type 3, Niemann-Pick disease type C, pantothenate kinase-associated neurodegeneration, Tay-Sachs disease and Wilson's disease (all recessive). Wilson's disease is particularly important since cognition can improve with treatment.

At all ages, a substantial proportion of patients who complain of memory difficulty or other cognitive symptoms are suffering from depression rather than a neurodegenerative disease. Vitamin deficiencies and chronic infections may also occur at any age; they usually cause other symptoms before dementia occurs, but occasionally mimic degenerative dementia. These include deficiencies of vitamin B12, folate or niacin, and infective causes including cryptococcal meningitis, HIV, Lyme disease, progressive multifocal leukoencephalopathy, subacute sclerosing panencephalitis, syphilis and Whipple's disease.

Rapidly progressive dementia

Creutzfeldt-Jakob disease typically causes a dementia which worsens over weeks to months. The common causes of slowly progressive dementia also sometimes present with rapid progression: Alzheimer's disease, dementia with Lewy bodies, frontotemporal lobar degeneration (including corticobasal degeneration and progressive supranuclear palsy).

On the other hand, encephalopathy or delirium may develop relatively slowly and resemble dementia. Possible causes include brain infection (viral encephalitis, subacute sclerosing panencephalitis, Whipple's disease) or inflammation (limbic encephalitis, Hashimoto's encephalopathy, cerebral vasculitis); tumors such as lymphoma or glioma; drug toxicity (e.g. anticonvulsant drugs); metabolic causes such as liver failure or kidney failure; and chronic subdural hematoma.

Dementia as a feature of other conditions

There are many other medical and neurological conditions in which dementia only occurs late in the illness, or as a minor feature. For example, a proportion of patients with Parkinson's disease develop dementia, though widely varying figures are quoted for this proportion.[citation needed] When dementia occurs in Parkinson's disease, the underlying cause may be dementia with Lewy bodies or Alzheimer's disease, or both.[12] Cognitive impairment also occurs in the Parkinson-plus syndromes of progressive supranuclear palsy and corticobasal degeneration (and the same underlying pathology may cause the clinical syndromes of frontotemporal lobar degeneration). Chronic inflammatory conditions of the brain may affect cognition in the long term, including Behçet's disease, multiple sclerosis, sarcoidosis, Sjögren's syndrome and systemic lupus erythematosus. Although the acute porphyrias may cause episodes of confusion and psychiatric disturbance, dementia is a rare feature of these rare diseases.[13]

Aside from those mentioned above, inherited conditions which may cause dementia alongside other features include:[14]

Diagnosis

Proper differential diagnosis between the types of dementia (cortical and subcortical) will require, at the least, referral to a specialist, e.g., a geriatric internist, geriatric psychiatrist, neurologist, neuropsychologist or geropsychologist.[citation needed] However, there exist some brief tests (5–15 minutes) that have reasonable reliability and can be used in the office or other setting to screen cognitive status for deficits that are considered pathological. Examples of such tests include the abbreviated mental test score (AMTS), the mini mental state examination (MMSE), Modified Mini-Mental State Examination (3MS),[15] the Cognitive Abilities Screening Instrument (CASI),[16] and the clock drawing test.[17] An AMTS score of less than six (out of a possible score of ten) and an MMSE score under 24 (out of a possible score of 30) suggests a need for further evaluation. Scores must be interpreted in the context of the person's educational and other background, and the particular circumstances; for example, a person highly depressed or in great pain will not be expected to do well on many tests of mental ability.

Mini-mental state examination

Main article: Mini-mental state examination

The U.S. Preventive Services Task Force (USPSTF) reviewed tests for cognitive impairment and concluded:[18]

  • MMSE
sensitivity 71% to 92%
specificity 56% to 96%

Modified Mini-Mental State examination (3MS)

A copy of the 3MS is online.[19] A meta-analysis concluded that the Modified Mini-Mental State (3MS) examination has:[20]

sensitivity 83% to 93.5%
specificity 85% to 90%

Abbreviated mental test score

Main article: abbreviated mental test score

A meta-analysis concluded:[20]

sensitivity 73% to 100%
specificity 71% to 100%

Duration of symptoms

Duration of symptoms must normally exceed six months for a diagnosis of dementia or organic brain syndrome to be made.

Other examinations

Many other tests have been studied[21][22][23] including the clock-drawing test (example form). Although some may emerge as better alternatives to the MMSE, presently the MMSE is the best studied. However, access to the MMSE is now limited by enforcement of its copyright.[citation needed]

Another approach to screening for dementia is to ask an informant (relative or other supporter) to fill out a questionnaire about the person's everyday cognitive functioning. Informant questionnaires provide complementary information to brief cognitive tests. Probably the best known questionnaire of this sort is the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE).[24]

The General Practitioner Assessment Of Cognition combines both, a patient assessment and an informant interview. It was specifically designed for the use in the primary care setting and is also available as a web-based test. It can be accessed at www.gpcog.com.au.

Further evaluation includes retesting at another date, and administration of other (and sometimes more complex) tests of mental function, such as formal neuropsychological testing.

Laboratory tests

Routine blood tests are also usually performed to rule out treatable causes. These tests include vitamin B12, folic acid, thyroid-stimulating hormone (TSH), C-reactive protein, full blood count, electrolytes, calcium, renal function, and liver enzymes. Abnormalities may suggest vitamin deficiency, infection or other problems that commonly cause confusion or disorientation in the elderly. The problem is complicated by the fact that these cause confusion more often in persons who have early dementia, so that "reversal" of such problems may ultimately only be temporary.[citation needed]

Testing for alcohol and other known dementia-inducing drugs may be indicated.

Imaging

A CT scan or magnetic resonance imaging (MRI scan) is commonly performed, although these modalities do not have optimal sensitivity for the diffuse metabolic changes associated with dementia in a patient that shows no gross neurological problems (such as paralysis or weakness) on neurological exam. CT or MRI may suggest normal pressure hydrocephalus, a potentially reversible cause of dementia, and can yield information relevant to other types of dementia, such as infarction (stroke) that would point at a vascular type of dementia.

The functional neuroimaging modalities of SPECT and PET are more useful in assessing long-standing cognitive dysfunction, since they have shown similar ability to diagnose dementia as a clinical exam.[25] The ability of SPECT to differentiate the vascular cause from the Alzheimer's disease cause of dementias, appears to be superior to differentiation by clinical exam.[26]

Recent research has established the value of PET imaging using carbon-11 Pittsburgh Compound B as a contrast medium (PIB-PET) in predictive diagnosis of various kinds of dementia, in particular Alzheimer's disease. Studies from Australia have found PIB-PET to be 86% accurate in predicting which patients with mild cognitive impairment would develop Alzheimer's disease within two years. In another study, carried out using 66 patients seen at the University of Michigan, PET studies using either PIB or another contrast agent, carbon-11 dihydrotetrabenazine (DTBZ), led to more accurate diagnosis for more than one-fourth of patients with mild cognitive impairment or mild dementia.[27]

Prevention

Main article: Prevention of dementia

It appears that the regular moderate consumption of alcohol (beer, wine, or distilled spirits) and a Mediterranean diet may reduce risk.[28][29][30][31] A study has shown a link between high blood pressure and developing dementia. The study, published in the Lancet Neurology journal July 2008, found that blood pressure lowering medication reduced dementia by 13%.[32][33]

Brain-derived neurotrophic factor (BDNF) expression is associated with some dementia types.[34][35][36]

Management

Except for the treatable types listed above, there is no cure to this illness. Cholinesterase inhibitors are often used early in the disease course. Cognitive and behavioral interventions may also be appropriate. Educating and providing emotional support to the caregiver (or carer) is of importance as well (see also elderly care).

Some studies worldwide have found that music therapy may be useful in helping patients with dementia.[37][38][39][40][41]

Pain and dementia

See also: Assessment in nonverbal patients

As they age, people experience more health problems, and most health problems associated with aging carry a substantial burden of pain; so, between 25% and 50% of older adults experience persistent pain. Seniors with dementia experience the same prevalence of conditions likely to cause pain as seniors without dementia.[42] Pain is often overlooked in older adults and, when screened for, often poorly assessed, especially among those with dementia.[42][43] Beyond the issue of humane care, unrelieved pain has functional implications. Persistent pain can lead to decreased ambulation, depressed mood, sleep disturbances, impaired appetite and exacerbation of cognitive impairment,[43] and pain-related interference with activity is a factor contributing to falls in the elderly.[42][44]

Although persistent pain in the person with dementia is difficult to communicate, diagnose and treat, failure to address persistent pain has profound functional, psychosocial and quality of life implications for this vulnerable population. Health professionals often lack the skills and usually lack the time needed to recognize, accurately assess and adequately monitor pain in people with dementia.[42][45] Family members and friends can make a valuable contribution to the care of a person with dementia by learning to recognize and assess their pain. Educational resources (such as the Understand Pain and Dementia tutorial) and observational assessment tools are available.[42][46][47]

Bilingualism

A Canadian study found that a lifetime of bilingualism has a marked influence on delaying the onset of dementia by an average of four years when compared to monolingual patients. The researchers determined that the onset of dementia symptoms in the monolingual group occurred at the mean age of 71.4, while the bilingual group was 75.5 years. The difference remained even after considering the possible effect of cultural differences, immigration, formal education, employment and even gender as influences in the results.[48]

Medications

  • Acetylcholinesterase inhibitors: Tacrine (Cognex), donepezil (Aricept), galantamine (Razadyne), and rivastigmine (Exelon) are approved by the United States Food and Drug Administration (FDA) for treatment of dementia induced by Alzheimer's disease. They may be useful for other similar diseases causing dementia such as Parkinsons or vascular dementia.[49]
  • N-methyl-D-aspartate Blockers. Memantine (Namenda) is a drug representative of this class. It can be used in combination with acetylcholinesterase inhibitors.[50][51]

Off label

  • Amyloid deposit inhibitors: Minocycline and Clioquinoline, antibiotics, may help reduce amyloid deposits in the brains of persons with Alzheimer's disease.[52]
  • Antidepressant drugs: Depression is frequently associated with dementia and generally worsens the degree of cognitive and behavioral impairment. Antidepressants effectively treat the cognitive and behavioral symptoms of depression in patients with Alzheimer's disease,[53] but evidence for their use in other forms of dementia is weak.[54]
  • Anxiolytic drugs: Many patients with dementia experience anxiety symptoms. Although benzodiazepines like diazepam (Valium) have been used for treating anxiety in other situations, they are often avoided because they may increase agitation in persons with dementia and are likely to worsen cognitive problems or are too sedating. Buspirone (Buspar) is often initially tried for mild-to-moderate anxiety.[citation needed] There is little evidence for the effectiveness of benzodiazepines in dementia, whereas there is evidence for the effectivess of antipsychotics (at low doses).[55]

    Selegiline, a drug used primarily in the treatment of Parkinson's disease, appears to slow the development of dementia. Selegiline is thought to act as an antioxidant, preventing free radical damage. However, it also acts as a stimulant, making it difficult to determine whether the delay in onset of dementia symptoms is due to protection from free radicals or to the general elevation of brain activity from the stimulant effect.[56]

  • Antipsychotic drugs: Both typical antipsychotics (such as Haloperidol) and atypical antipsychotics such as (risperidone) increase the risk of death in dementia-associated psychosis.[57] This means that any use of antipsychotic medication for dementia-associated psychosis is off-label and should only be considered after discussing the risks and benefits of treatment with these drugs, and after other treatment modalities have failed. In the UK around 144,000 dementia sufferers are unnecessarily prescribed antipsychotic drugs, around 2000 patients die as a result of taking the drugs each year.[58]

Services

Adult daycare centers as well as special care units in nursing homes often provide specialized care for dementia patients. Adult daycare centers offer supervision, recreation, meals, and limited health care to participants, as well as providing respite for caregivers.

Prognosis

Severe dementia is frequently complicated by pneumonia, febrile illnesses, and eating problems. Life expectancy is short at 18 months.[59]

Epidemiology

Disability-adjusted life year for Alzheimer and other dementias per 100,000 inhabitants in 2002.
  no data
  ≤ 50
  50-70
  70-90
  90-110
  110-130
  130-150
  150-170
  170-190
  190-210
  210-230
  230-250
  ≥ 250

See also

References

Notes

  1. ^ Fowler, Timothy J. (2003). Clinical Neurology. Oxford University Press Inc. ISBN 0340807989. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |pg= ignored (help)
  2. ^ Berrios GE (1987). "Dementia during the seventeenth and eighteenth centuries: a conceptual history". Psychological Medicine. 17 (4): 829–37. doi:10.1017/S0033291700000623. PMID 3324141. {{cite journal}}: Unknown parameter |month= ignored (help)
  3. ^ "Dementia definition". MDGuidelines. Reed Group. Retrieved 2009-06-04.
  4. ^ Gleason OC (2003). "Delirium". American Family Physician. 67 (5): 1027–34. PMID 12643363. {{cite journal}}: Unknown parameter |month= ignored (help)
  5. ^ Hulse GK, Lautenschlager NT, Tait RJ, Almeida OP (2005). "Dementia associated with alcohol and other drug use". Int Psychogeriatr. 17 (Suppl 1): S109–27. doi:10.1017/S1041610205001985. PMID 16240487.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ Peters R, Peters J, Warner J, Beckett N, Bulpitt C (2008). "Alcohol, dementia and cognitive decline in the elderly: a systematic review". Age Ageing. 37 (5): 505–12. doi:10.1093/ageing/afn095. PMID 18487267. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  7. ^ Calleo J, Stanley M (2008). "Anxiety Disorders in Later Life Differentiated Diagnosis and Treatment Strategies". Psychiatric Times. 25 (8). {{cite journal}}: line feed character in |title= at position 32 (help)
  8. ^ Shub, Denis; Kunik, Mark E (April 16, 2009). "Psychiatric Comorbidity in Persons With Dementia: Assessment and Treatment Strategies". Psychiatric Times. 26 (4).{{cite journal}}: CS1 maint: date and year (link)
  9. ^ Wakisaka Y; et al. (2003). "Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study". Acta Neuropathol. 106 (4): 374–82. doi:10.1007/s00401-003-0750-x. PMID 12904992. {{cite journal}}: Explicit use of et al. in: |author= (help)
  10. ^ White L; et al. (2002). "Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants". Ann N Y Acad Sci. 977 (9): 9–23. doi:10.1111/j.1749-6632.2002.tb04794.x. PMID 12480729. {{cite journal}}: Explicit use of et al. in: |author= (help)
  11. ^ Ratnavalli E; et al. (2002). "The prevalence of frontotemporal dementia". Neurology. 58 (11): 1615–21. PMID 12058088. {{cite journal}}: Explicit use of et al. in: |author= (help)
  12. ^ Galvin JE; et al. (2006). "Clinical phenotype of Parkinson disease dementia". Neurology. 67 (9): 1605–11. doi:10.1212/01.wnl.0000242630.52203.8f. PMID 17101891. {{cite journal}}: Explicit use of et al. in: |author= (help)
  13. ^ Gibbons D; et al. "Porphyria and dementia: a case report" (PDF). Ir J Psych Med. 20 (3): 96–99. {{cite journal}}: Explicit use of et al. in: |author= (help)
  14. ^ Lamont P (2004). "Cognitive Decline in a Young Adult with Pre-Existent Developmental Delay – What the Adult Neurologist Needs to Know". Practical Neurology. 4: 70–87. doi:10.1111/j.1474-7766.2004.02-206.x.
  15. ^ Teng EL, Chui HC (1987). "The Modified Mini-Mental State (3MS) examination". The Journal of Clinical Psychiatry. 48 (8): 314–8. PMID 3611032. {{cite journal}}: Unknown parameter |month= ignored (help)
  16. ^ Teng EL, Hasegawa K, Homma A; et al. (1994). "The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia". International Psychogeriatrics / IPA. 6 (1): 45–58, discussion 62. doi:10.1017/S1041610294001602. PMID 8054493. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  17. ^ Royall, D; Cordes, J.; Polk, M. (1998). "CLOX: an executive clock drawing task". J Neurol Neurosurg Psychiatry. 64 (5): 588–94. doi:10.1136/jnnp.64.5.588. PMID 9598672.
  18. ^ Boustani, M; Peterson, B; Hanson, L; Harris, R; & Lohr, K (3 June 2003). "Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force". Ann Intern Med. 138 (11): 927–37. PMID 12779304.
  19. ^ "Appendix: The Modified Mini-Mental State (3MS)". Retrieved 2007-09-06.
  20. ^ a b Cullen B, O'Neill B, Evans JJ, Coen RF, Lawlor BA (2007). "A review of screening tests for cognitive impairment". Journal of Neurology, Neurosurgery, and Psychiatry. 78 (8): 790–9. doi:10.1136/jnnp.2006.095414. PMID 17178826. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  21. ^ Sager MA, Hermann BP, La Rue A, Woodard JL (2006). "Screening for dementia in community-based memory clinics" (PDF). WMJ: Official Publication of the State Medical Society of Wisconsin. 105 (7): 25–9. PMID 17163083. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  22. ^ Fleisher, A; Sowell, B; Taylor, C; Gamst, A; Petersen, R; Thal, L (2007). "Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment". Neurology. 68 (19): 1588. doi:10.1212/01.wnl.0000258542.58725.4c. PMID 17287448.
  23. ^ Karlawish, J & Clark, C (2003). "Diagnostic evaluation of elderly patients with mild memory problems". Ann Intern Med. 138 (5): 411–9. PMID 12614094.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  24. ^ Jorm AF (2004). "The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review". International Psychogeriatrics / IPA. 16 (3): 275–93. doi:10.1017/S1041610204000390. PMID 15559753. {{cite journal}}: Unknown parameter |month= ignored (help)
  25. ^ Bonte, FJ (2006). "Tc-99m HMPAO SPECT in the differential diagnosis of the dementias with histopathologic confirmation". Clinical Nuclear Medicine. 31 (7): 376–8. doi:10.1097/01.rlu.0000222736.81365.63. PMID 16785801. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  26. ^ Dougall, NJ (2004). "Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia". The American Journal of Geriatric Psychiatry. 12 (6): 554–70. doi:10.1176/appi.ajgp.12.6.554. PMID 15545324. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  27. ^ Abella HA (June 16, 2009). "Report from SNM: PET imaging of brain chemistry bolsters characterization of dementias". Diagnostic Imaging.
  28. ^ Mukamal KJ, Kuller LH, Fitzpatrick AL, Longstreth WT, Mittleman MA, Siscovick DS (2003). "Prospective study of alcohol consumption and risk of dementia in older adults". JAMA. 289 (11): 1405–13. doi:10.1001/jama.289.11.1405. PMID 12636463. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  29. ^ Ganguli M, Vander Bilt J, Saxton JA, Shen C, Dodge HH (2005). "Alcohol consumption and cognitive function in late life: a longitudinal community study". Neurology. 65 (8): 1210–7. doi:10.1212/01.wnl.0000180520.35181.24. PMID 16247047. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  30. ^ Huang W, Qiu C, Winblad B, Fratiglioni L (2002). "Alcohol consumption and incidence of dementia in a community sample aged 75 years and older". J Clin Epidemiol. 55 (10): 959–64. doi:10.1016/S0895-4356(02)00462-6. PMID 12464371. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  31. ^ Sofi F, Cesari F, Abbate R, Gensini GF, Casini A (2008). "Adherence to Mediterranean diet and health status: meta-analysis". BMJ. 337: a1344. doi:10.1136/bmj.a1344. PMC 2533524. PMID 18786971.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. ^ Fillit H, Nash DT, Rundek T, Zuckerman A (2008). "Cardiovascular risk factors and dementia". Am J Geriatr Pharmacother. 6 (2): 100–18. doi:10.1016/j.amjopharm.2008.06.004. PMID 18675769. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  33. ^ Hyvet, investigators; Burch; Fletcher; Bulpitt (2008). "Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial". Lancet Neurol. 7 (8): 683–9. doi:10.1016/S1474-4422(08)70143-1. PMID 18614402. {{cite journal}}: More than one of |author= and |last1= specified (help); Unknown parameter |month= ignored (help)
  34. ^ Hu, Y; Russek, SJ (2008). "BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation". Journal of neurochemistry. 105 (1): 1–17. doi:10.1111/j.1471-4159.2008.05237.x. PMID 18208542.
  35. ^ Schindowski, K; Belarbi, K; Buée, L (2008). "Neurotrophic factors in Alzheimer's disease: role of axonal transport". Genes, brain, and behavior. 7 (Suppl 1): 43–56. doi:10.1111/j.1601-183X.2007.00378.x. PMC 2228393. PMID 18184369. {{cite journal}}: Unknown parameter |doi_brokendate= ignored (|doi-broken-date= suggested) (help)
  36. ^ Tapia-Arancibia, L; Aliaga, E; Silhol, M; Arancibia, S (2008). "New insights into brain BDNF function in normal aging and Alzheimer disease". Brain research reviews. 59 (1): 201–20. doi:10.1016/j.brainresrev.2008.07.007. PMID 18708092.
  37. ^ Aldridge, David (2000). Music Therapy in Dementia Care. London: Jessica Kingsley Publishers. ISBN 1-85302-776-6.
  38. ^ Tuet, R.W.K., Lam, L.C.W. (2006). "A preliminary study of the effects of music therapy on agitation in Chinese patients with dementia". Hong Kong Journal of Psychiatry. 16 (3). {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  39. ^ Watanabe, Tomoyuki; et al. (2005). "Effects of music therapy for dementia: A systematic review" (PDF). Aichi University of Education Research Reports (in Japanese). 55: 57–61. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)
  40. ^ Koger, Susan M.; Chapin Kathyn; Brotons, Melissa (1999). "Is Music Therapy an Effective Intervention for Dementia? : A Meta-Analytic Review of Literature". Journal of Music Therapy. 36 (1): 2–15. PMID 10519841. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  41. ^ Remington, Ruth (2002). "Calming Music and Hand Massage With Agitated Elderly". Nursing Research. 51 (5): 317–23. doi:10.1097/00006199-200209000-00008. PMID 12352780. {{cite journal}}: Unknown parameter |month= ignored (help)
  42. ^ a b c d e Hadjistavropoulos, T; Herr, K; Turk, DC; Fine, PG; Dworkin, RH; Helme, R; Jackson, K; Parmelee, PA; Rudy, TE; et al. (2007). "An interdisciplinary expert consensus statement on assessment of pain in older persons". Clinical Journal of Pain. 23 (1 suppl): S1–43. doi:10.1097/AJP.0b013e31802be869. PMID 17179836. {{cite journal}}: Explicit use of et al. in: |first= (help)
  43. ^ a b Shega, J; Emanuel, L; Vargish, L; Levine, S.K.; Bursch, H; Herr, K; Karp, J.F.; Weiner, D.K. (2007). "Pain in persons with dementia: complex, common, and challenging". Journal of Pain. 8 (5): 373–8. doi:10.1016/j.jpain.2007.03.003. PMID 17485039.
  44. ^ Blyth, F; Cumming, M.R.; Mitchell, P; Wang, J.J. (2007). "Pain and falls in older people". European Journal of Pain. 11 (5): 564–71. doi:10.1016/j.ejpain.2006.08.001. PMID 17015026.
  45. ^ Brown, C. (2009). "Pain, aging and dementia: The crisis is looming, but are we ready?". British Journal of Occupational Therapy. 72 (8): 371–75.
  46. ^ Herr, K; Bjoro, K; Decker, S; Wang (2006). "Tools for assessment of pain in nonverbal older adults with dementia: a state-of-the-science review". Journal of pain and symptom management. 31 (2): 170–92. doi:10.1016/j.jpainsymman.2005.07.001. PMID 16488350.
  47. ^ Stolee, P; Hillier, LM; Esbaugh; Bol, N; McKellar, L; Gauthier, N; et al. (2005). "Instruments for the assessment of pain in older persons with cognitive impairment". Journal of the American geriatrics society. 53 (2): 319–26. doi:10.1111/j.1532-5415.2005.53121.x. PMID 15673359. {{cite journal}}: Explicit use of et al. in: |first3= (help)
  48. ^ "Bilingualism Has Protective Effect In Delaying Onset Of Dementia By Four Years, Canadian Study Shows". Medical News Today. 2007-01-11. Retrieved 2007-01-16.
  49. ^ Lleó A, Greenberg SM, Growdon JH (2006). "Current pharmacotherapy for Alzheimer's disease". Annu. Rev. Med. 57: 513–33. doi:10.1146/annurev.med.57.121304.131442. PMID 16409164.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  50. ^ Raina P, Santaguida P, Ismaila A; et al. (2008). "Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline". Annals of Internal Medicine. 148 (5): 379–97. PMID 18316756. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  51. ^ Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008). "Long-term course and effectiveness of combination therapy in Alzheimer disease". Alzheimer Disease and Associated Disorders. 22 (3): 209–21. doi:10.1097/WAD.0b013e31816653bc. PMC 2718545. PMID 18580597.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  52. ^ Choi Y, Kim HS, Shin KY, YH; Kim; Suh; et al. (2007). "Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models". Neuropsychopharmacology. 32 (11): 2393–404. doi:10.1038/sj.npp.1301377. PMID 17406652. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  53. ^ Thompson S, Herrmann N, Rapoport MJ, Lanctôt KL (2007). "Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis" (PDF). Canadian Journal of Psychiatry. 52 (4): 248–55. PMID 17500306. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  54. ^ Bains J, Birks JS, Dening TR (2002). "The efficacy of antidepressants in the treatment of depression in dementia". Cochrane Database of Systematic Reviews (4): CD003944. doi:10.1002/14651858.CD003944. PMID 12519625.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  55. ^ Lolk A, Gulmann NC (2006). "[Psychopharmacological treatment of behavioral and psychological symptoms in dementia]". Ugeskr Laeg (in Danish). 168 (40): 3429–32. PMID 17032610.
  56. ^ Riederer P, Lachenmayer L (2003). "Selegiline's neuroprotective capacity revisited". Journal of Neural Transmission. 110 (11): 1273–8. doi:10.1007/s00702-003-0083-x. PMID 14628191. {{cite journal}}: Unknown parameter |month= ignored (help)
  57. ^ "FDA MedWatch - 2008 Safety Alerts for Human Medical Products". FDA.
  58. ^ Bowcott, Owen (2009-11-12). "Chemical restraints killing dementia patients". London: Guardian. Retrieved 2010-05-01.
  59. ^ Mitchell SL, Teno JM, Kiely DK; et al. (2009). "The clinical course of advanced dementia". N. Engl. J. Med. 361 (16): 1529–38. doi:10.1056/NEJMoa0902234. PMC 2778850. PMID 19828530. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Dementia&oldid=368142497"